TScan Therapeutics, Inc.
NASDAQ:TCRXBiotechnology
+$0.02 today
- Market cap
- $50.37M
- Beta
- 1.03
- P/E (TTM)
- -1.0
- EPS (TTM)
- -$0.96
Volume 0.00M
Average 0.81M
TCRX Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
TScan Therapeutics, Inc.NASDAQ: TCRX
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue dips below year-ago levels
Q1 FY2026 revenue of $982K fell 54.8% year over year, behind the +106.7% change in trailing-twelve-month revenue. Sequentially, it fell 61.7% from the prior quarter. Over 3 fiscal years it compounded at -8.6% a year.
Context
- Revenue increased in 2 of the last 3 fiscal years.
What to watch
Whether revenue reaches the consensus estimate from 4 analysts of $7.56M (-26.8%) for the fiscal year ending Dec 2026, a slowdown from the +266.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $982K-61.7% QoQ
- Last fiscal yearDec 2025
- $10.33M+266.7% YoY
- LTMMar 2026
- $9.14M+106.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -54.8% | -39.0% | +15.7 pp |
| 1 year | +266.7% | -26.8% | -293.5 pp |
| 3-year CAGR | -8.6% | +36.5% | +45.1 pp |
| 5-year CAGR | +53.0% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 10.33M USD
- Year-over-year change
- +266.7%
- 4-year CAGR
- +0.5%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 10.33M | +266.7% |
| FY2024 | 2024-12-31 | 2.82M | -86.6% |
| FY2023 | 2023-12-31 | 21.05M | +55.5% |
| FY2022 | 2022-12-31 | 13.54M | +33.5% |
| FY2021 | 2021-12-31 | 10.14M | — |
Revenue vs competitors
How TCRX compares with its peers on the latest reported figures
- TCRX's LTM Mar 2026 revenue of $9.14M is the 3rd highest of the 10 companies compared; the peer median is $0.
- Its year-over-year change of +106.7% is the 2nd highest of 4, against a peer median of +14.5%.
- Over three fiscal years its annual growth of -8.6% compares with a peer median of -0.7%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $255.61M | +439.3% | +1204.0% | |
| LTM Mar 2026 | $66.16M | +14.5% | -5.8% | |
| LTM Mar 2026 | $9.14M | +106.7% | -8.6% | |
| LTM Apr 2026 | $1.8M | -24.8% | -0.7% | |
| LTM Mar 2026 | $0 | — | — | |
| LTM Mar 2026 | $0 | — | — | |
| LTM Mar 2026 | $0 | — | — | |
| LTM Mar 2026 | $0 | — | — | |
| LTM Mar 2026 | $0 | — | — | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $0 | — | — |
| Peer median (excluding TCRX) | $0 | +14.5% | -0.7% | |
Competitors are the stored peer set for TCRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 10.14M | 13.54M | 21.05M | 2.82M | 10.33M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 2.87M |
| Gross Profit | 10.14M | 13.54M | 21.05M | 2.82M | 7.46M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 72.2% |
| Research & Development | 44.95M | 59.82M | 88.15M | 107.35M | 114.15M |
| Selling, General & Admin | 13.83M | 20.35M | 25.49M | 29.56M | 31.99M |
| Operating Expenses | 58.78M | 80.17M | 114.51M | 137.64M | 143.27M |
| Depreciation & Amortization | 3.33M | 5.14M | 5.36M | 4.11M | 2.87M |
| EBITDA | (45.3M) | (59.91M) | (80.1M) | (119.74M) | (124.13M) |
| EBITDA Margin | -446.7% | -442.6% | -380.5% | -4252.1% | -1202.2% |
| Operating Income | (48.64M) | (66.64M) | (93.46M) | (134.82M) | (135.81M) |
| Operating Margin | -479.6% | -492.3% | -444.0% | -4787.7% | -1315.4% |
| Interest Income | 16K | 1.59M | 8M | 12.07M | 8.82M |
| Interest Expense | 0 | 1.18M | 3.76M | 3.65M | 2.77M |
| Other Income / Expenses | 16K | 415K | 4.24M | 7.32M | 6.05M |
| Income Before Tax | (48.63M) | (66.22M) | (89.22M) | (127.5M) | (129.77M) |
| Pre-Tax Margin | -479.5% | -489.3% | -423.9% | -4527.7% | -1256.8% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (48.63M) | (66.22M) | (89.22M) | (127.5M) | (129.77M) |
| Net Margin | -479.5% | -489.3% | -423.9% | -4527.7% | -1256.8% |
| EPS (Basic) | (2.03) | (2.74) | (1.36) | (1.14) | (1.00) |
| EPS (Diluted) | (2.03) | (2.74) | (1.36) | (1.14) | (1.00) |
| Weighted Avg Shares | 23.91M | 24.05M | 65.6M | 111.99M | 129.86M |
| Weighted Avg Shares (Diluted) | 23.91M | 24.05M | 65.6M | 111.99M | 129.86M |
TScan Therapeutics, Inc.
NASDAQ:TCRX
Intrinsic Alpha fair value
Locked
Current Price
$0.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.